Central pain syndrome
Methodology & AI Transparency ⓘ
Central pain syndrome Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Central pain syndrome is an ICD-10-CM indexed diagnosis (G89.0) within Neuropathy, Fibromyalgia & Chronic Pain.
- 2 Real-world patient consensus: Mapped to Neuropathy, Fibromyalgia & Chronic Pain under ICD-10-CM G89.0 for Central pain syndrome clinical workups.
- 3 Typical cash cost range: Clinicians assessing Central pain syndrome focus on peripheral small-fiber or in Central pain syndrome (G89.0: large-fiber axonal injury) and targeted history.
- 4 Top reported side effects / signs: Follow-up benchmark in Central pain syndrome: maintaining HbA1c & 2-Hour in Central pain syndrome (G89.0: Glucose Tolerance) within HbA1c < 5.6% (G89.0).
Ask our AI Specialists anything about Central pain syndrome
What Is Central pain syndrome?
Central pain syndrome is an ICD-10-CM indexed diagnosis (G89.0) within Neuropathy, Fibromyalgia & Chronic Pain. Clinical evaluation centers on metabolic/autoimmune neuropathy lab in Central pain syndrome (G89.0: panels) alongside serial HbA1c & 2-Hour in Central pain syndrome (G89.0: Glucose Tolerance) tracking (HbA1c < 5.6% (G89.0)) to guide individualized care.
Pathophysiology, Underlying Causes & Clinical Presentation
Tissue-level etiology in Central pain syndrome (G89.0) features peripheral small-fiber or in Central pain syndrome (G89.0: large-fiber axonal injury). therapeutic stabilization in chronic pain & nerves is verified against Vitamin B12 & in Central pain syndrome (G89.0: Methylmalonic Acid).
Common Symptoms & Clinical Signs
- • Presentation of Central pain syndrome (G89.0): widespread musculoskeletal tender in Central pain syndrome (G89.0: points accompanied by)
- • Secondary Central pain syndrome clinical sign: localized nerve entrapment in Central pain syndrome (G89.0: numbness or radiating)
- • Symptom flares in Central pain syndrome correlating with HbA1c & 2-Hour in Central pain syndrome (G89.0: Glucose Tolerance) deviation outside HbA1c < 5.6% (G89.0)
- • Functional chronic pain & nerves impact requiring metabolic/autoimmune neuropathy lab in Central pain syndrome (G89.0: panels) evaluation (G89.0)
Central pain syndrome Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | G89.0 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Neuropathy, Fibromyalgia & Chronic Pain | NLM Clinical Tables |
| Diagnostic / Lab Marker: HbA1c & 2-Hour in Central pain syndrome (G89.0: Glucose Tolerance) | HbA1c < 5.6% (G89.0) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Vitamin B12 & in Central pain syndrome (G89.0: Methylmalonic Acid) | B12 > 500 pg/mL (G89.0) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: hs-CRP & ESR in Central pain syndrome (G89.0: Inflammatory Check) | hs-CRP < 1.0 mg/L (G89.0) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Central pain syndrome
Treatment selection for Central pain syndrome depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Central pain syndrome)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Is adenotonsillectomy effective in improving central apnea events in patients: What a 1,287-Participant Study Found Adenotonsillectomy improves central apnea events in patients with OSA but not in those with comorbidities. European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery • 2023-12-15 • Meta-Analysis | N = 1,287 | 94/100 | PMID 37642712 ↗ |
| New Insights on Participant, site personnel and sponsor perspectives on decentralized trial: What a 486-Participant Study Found RVs influenced the decision to pursue the trial in 13/31 participants. Amyotrophic lateral sclerosis & frontotemporal degeneration • 2025-11-15 • Phase III Randomized Trial | N = 486 | 93/100 | PMID 40576049 ↗ |
| New Insights on SGLT2 inhibitor or metformin as standard treatment in early-stage type 2: What a 2,072-Participant Study Found This decentralised RRCT in newly onset T2D demonstrates a highly feasible option for large-scale trials in the primary care setting, enabling representative participant recruitment. Diabetes, obesity & metabolism • 2026-02-15 • Randomized Controlled Trial | N = 2,072 | 90/100 | PMID 41311237 ↗ |
| Can This Approach Help? Inside the Latest Research on Central nervous system symptom burden and clinical implications for antiemetic CNS symptom burden was associated with suboptimal CINV control, while 5 mg of olanzapine maintained superior antiemetic efficacy across CNS symptom strata. The oncologist • 2026-09-09 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 42714265 ↗ |
| Can This Approach Help? Inside the Latest Research on Randomised controlled decentralised feasibility trial of a fixed low-dose The feasibility of this decentralised trial on BP lowering in patients at high risk for dementia is low. BMJ open • 2024-08-24 • Randomized Controlled Trial | Multi-cohort | 88/100 | PMID 39181551 ↗ |
Central pain syndrome Patient Community & “People Like Me” Threads
Filter Central pain syndrome community threads and patient logs by age, biological sex, dosage, and treatment duration.